drugset / Trial / NCT00806195
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
RandomizedParallel-groupOpen-labelPrevention
Summary
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
Timeline
- Start
- 2008-12
- Primary completion
- 2011-03
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MenACWY-CRM197 | Vaccine | 0.5 ml | Intramuscular |
| Background | DTaP (Diptheria, Tetanus, Pertussis) | Vaccine | — | — |
| Background | Hepatitis A Virus | Vaccine | — | — |
| Background | Hib (Haemophilus influenza b) | Vaccine | — | — |
| Background | IPV (Inactivated Polio Vaccine) | Vaccine | — | — |
| Background | MMR (Measles, Mumps, and Rubella) | Vaccine | — | — |
| Background | Pneumococcal conjugate | Vaccine | — | — |
| Background | Varicella | Vaccine | — | — |